Technology evaluation: DCVax, Northwest biotherapeutics

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations

Abstract

DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.

Original languageEnglish (US)
Pages (from-to)403-407
Number of pages5
JournalCurrent Opinion in Molecular Therapeutics
Volume4
Issue number4
StatePublished - Aug 1 2002

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Technology evaluation: DCVax, Northwest biotherapeutics'. Together they form a unique fingerprint.

Cite this